NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is Frontrunner in the Delivery of Non-Psychoactive Cannabinoids

Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights

Lexaria Biosciences Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has enhanced the ability of cannabinoid-products companies to deliver active ingredients to the body with its patent-protected technology. This technology is already being applied to the use of non-psychoactive cannabinoids, yielding a high-absorption hemp oil formula that is a source of omega and fatty acids, and patents are pending for tetrahydrocannabinol (THC) and other psychoactive cannabinoids along with nicotine and nonsteroidal anti-inflammatory drugs. An article discussing this reads: “The patent awarded to LXRP for the delivery of all non-psychoactive cannabinoids makes Lexaria the first company in the world to achieve this accomplishment. Awarded in the U.S. and Australia, it is now pending in 44 other countries while supporting research and development on cannabinoids across the industry. The company has filed 19 patent applications in the U.S. and internationally. It also expects additional patent acceptances and issuances in 2017 and over the coming years. In fact, Lexaria has out-licensed the technology as part of its royalty business model, allowing third-party partners and distributors to profit and support their own developments. The numerous deals already signed include those in various state markets, including California, Colorado and Nevada, and a distribution agreement for CBD chewables in Japan and South Korea. Lexaria’s first royalty agreement was with a fast-growing startup, but current negotiations are with larger, more established enterprises. Lexaria is expanding its global reach and expects to continue seeing growth in business deals in broader industry sectors with more well-known consumer brands.”

To view the full article, visit http://nnw.fm/F1eG1

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information about Lexaria, visit www.lexariabioscience.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217